Waystar (WAY) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Achieved 19% revenue growth in FY2024, with Q4 revenue up 18% year-over-year, surpassing long-term targets.
Completed a $1 billion IPO in June, strengthening financial position and enabling significant debt repayments.
Onboarded over 30,000 providers after a competitor's cyber attack, expanding the client base and driving cross-sell opportunities.
Launched AI-powered innovations, including Altitude AI, to enhance efficiency and client ROI.
Net revenue retention rate was 110% in Q4, with 1,203 clients generating over $100,000 in trailing 12-month revenue, up 15% year-over-year.
Financial highlights
Q4 revenue reached $244.1 million, up 18% year-over-year; full-year revenue was $944 million, up 19%.
Adjusted EBITDA for FY2024 was $383 million with a 40.6% margin; Q4 adjusted EBITDA was $100 million with a 41% margin.
GAAP net income for Q4 was $19.1 million; full-year GAAP net loss improved to $19.1 million from a $51 million loss in 2023.
Unlevered free cash flow was $80 million in Q4 and $265 million for the year, with a 69% EBITDA-to-cash conversion.
Net leverage ratio reduced to 2.8x at year-end, down from 6.6x a year earlier.
Outlook and guidance
FY2025 revenue guidance: $1.0–$1.016 billion, representing 7% reported and 10% normalized growth.
Adjusted EBITDA guidance for FY2025: $399–$407 million (40% margin).
Non-GAAP net income expected at $237–$243 million; non-GAAP EPS of $1.29–$1.32, reflecting 41% and 19% growth, respectively.
Volume growth expected to normalize to 1%-2% annually after elevated 2024 levels.
Guidance assumes ~$26 million stock-based compensation, ~$71 million interest expense, and a 21% non-GAAP effective tax rate.
Latest events from Waystar
- $1.25B AI-driven deal expands market by 15% and targets $15M+ in cost synergies.WAY
M&A Announcement9 Jul 2026 - AI-driven healthcare payments platform achieves strong growth and industry leadership.WAY
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - Q2 revenue up 20% to $234.5M, with strong margins and $1B+ debt reduction post-IPO.WAY
Q2 20248 Jul 2026 - Q2 revenue rose 15% to $270.7M, guidance was raised, and a $1.25B acquisition was announced.WAY
Q2 20258 Jul 2026 - Q3 revenue up 22% to $240.1M, 40% EBITDA margin, $1B+ IPO, and raised full-year guidance.WAY
Q3 20248 Jul 2026 - AI-powered automation and data integration drive efficiency, growth, and industry leadership.WAY
46th Annual William Blair Growth Stock Conference2 Jun 2026 - All board proposals passed, including director elections and annual say-on-pay votes.WAY
AGM 20261 Jun 2026 - Q1 2026 revenue rose 22% to $313.9M, with a 43% adjusted EBITDA margin and strong AI-driven growth.WAY
Q1 202630 Apr 2026 - Record revenue, AI innovation, and strong governance mark a transformative year.WAY
Proxy filing17 Apr 2026